Tabchi Samer, Kassouf Elie, Rassy Elie El, Kourie Hampig Raphael, Martin Jocelyne, Campeau Marie-Pierre, Tehfe Mustapha, Blais Normand
Medical Oncology Department, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Hotel Dieu de France University Hospital, Faculty of Medicine Saint Joseph University, Beirut, Lebanon.
Semin Oncol. 2017 Jun;44(3):163-177. doi: 10.1053/j.seminoncol.2017.10.009. Epub 2017 Oct 18.
Optimal management of patients with locally advanced non-small cell lung cancer remains challenging in the context of this heterogeneous disease. Despite aggressive therapeutic approaches, survival benefits are still unsatisfactory for what might be viewed as a localized malignancy. A combined modality approach offers patients superior outcomes, especially because technological advances and refined surgical procedures now provide better results with fewer complications. Nevertheless, several features of therapy remain controversial and lack formal prospective data. Traditional cytotoxic chemoradiation therapy may have reached a plateau and future perspectives opting to integrate molecularly targeted agents and immunotherapy might be the way to improve outcomes in this disease subset.
在这种异质性疾病的背景下，局部晚期非小细胞肺癌患者的最佳管理仍然具有挑战性。尽管采用了积极的治疗方法，但对于可能被视为局限性恶性肿瘤的疾病，生存获益仍然不尽人意。综合治疗方法能为患者带来更好的结果，特别是因为技术进步和精细的手术操作现在能以更少的并发症取得更好的效果。然而，治疗的几个方面仍存在争议且缺乏正式的前瞻性数据。传统的细胞毒性放化疗可能已达到平台期，未来选择整合分子靶向药物和免疫疗法可能是改善该疾病亚组预后的途径。
